Novartis completes $2B acquisition of Endocyte

Novartis AG completed its acquisition of Endocyte Inc. for $24 per share in cash, totaling approximately $2 billion. The deal was originally announced on October 17, 2018.

“Novartis AG completed the acquisition of Endocyte Inc.”uk.marketscreener.com

• 1 source
• uk.marketscreener.comNovartis AG completed the acquisition of Endocyte Inc. from Blue Chip Venture Company, Ltd., Sanderling Ventures, Burrill Venture Capital, Triathlon Medical Ventures and others.S&P Capital IQDec 20, 2018

Summarized from public sources; check the original articles before acting on it.